Completed NA INTERVENTIONAL 1-arm NCT04161807

Efficacy and Safety of Nerivio™ for Acute Treatment of Migraine in People With Chronic Migraine

Efficacy and Safety of Nerivio™, a Remote Electrical Neuromodulation Device, for Acute Treatment of Migraine in People With Chronic Migraine: an Open Label, Single Arm, Multicenter Study

Sponsor: Theranica

Conditions Chronic Migraine

Interventions Nerivio

Updated 10 times since 2019 Last updated: Jan 29, 2021 Started: Sep 18, 2019 Primary completion: Feb 18, 2020 Completion: Feb 18, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Chronic Migraine and is currently completed. Theranica leads this study, which shows 10 recorded versions since 2019 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Dec 2021 — Jul 2024 [monthly]

Completed NA
Mar 2021 — Dec 2021 [monthly]

Completed NA
Feb 2021 — Mar 2021 [monthly]

Completed NA

▶ Show 5 earlier versions

Jan 2021 — Feb 2021 [monthly]

Completed NA
Jun 2020 — Jan 2021 [monthly]

Completed NA

Status: Recruiting → Completed
Feb 2020 — Jun 2020 [monthly]

Recruiting NA
Jan 2020 — Feb 2020 [monthly]

Recruiting NA
Dec 2019 — Jan 2020 [monthly]

Recruiting NA

First recorded

Sep 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Theranica

Data source: Theranica

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Kfar Saba, Israel
• Lagrangeville, United States